Hematology/Oncology

Top Story

PSA testing rates differ among urologists, PCPs

PSA testing rates differ among urologists, PCPs
February 8, 2016

PSA testing rates have declined overall since the U.S. Preventive Services Task Force made a recommendation against the test, but these declines were greater among primary care physicians than urologists, according to a research letter published in JAMA Internal Medicine.

The U.S. Preventive Services Task Force (USPSTF) issued a recommendation against PSA testing for all men in 2011, according to study background. This recommendation has been linked to a decline in rates of PSA testing among men aged 50 years to 74 years, as well as a decline in cases of incident prostate cancer.

FDA News

FDA grants orphan drug designation to tazemetostat for treatment of malignant rhabdoid tumors

February 8, 2016
The FDA granted orphan drug status to tazemetostat for the treatment of malignant rhabdoid tumors, according to a press release from the agent’s manufacturer.The…
In the Journals

Addition of lenalidomide to standard therapy fails to prolong PFS in multiple myeloma

February 8, 2016
Combination lenalidomide, melphalan and prednisone, followed by lenalidomide maintenance, did not significantly extend PFS or improve response rates compared with…
In the Journals

Racial, treatment-related factors may influence bevacizumab efficacy in advanced cervical cancer

February 7, 2016
Use of Moore criteria may identify patients with advanced cervical cancer who may not benefit from treatment with bevacizumab, according to results of a study conducted…

Children’s Research Institute at Children’s Mercy appoints chief scientific officer

February 6, 2016
Tom Curran, PhD, FRS, has been hired as chief scientific officer and executive director of Children’s Research Institute at Children’s Mercy Kansas City.The…
More News Headlines »
CME

The Patient with Invasive Breast Cancer

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with invasive breast cancer.
More »
Meeting News CoverageVideo

VIDEO: Negative ACCORD trial results reinforce standard of care for rectal cancer

January 27, 2016
More »
Featured
CME

The Patient with Severe Leukocytosis

No commercial support for this activity.

Currently five tyrosine kinase inhibitors are available for use in patients with chronic myeloid leukemia (CML)…
More »
Current Issues
View the Current Issue
HemOnc Today
morganatic-roan